Status:
COMPLETED
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
Lead Sponsor:
AstraZeneca
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
18-130 years
Phase:
PHASE2
Brief Summary
This study is being carried out to see if ZD1839 is effective in treating metastatic breast cancer in combination with Nolvadex, and if so, how it compares with Nolvadex alone.
Eligibility Criteria
Inclusion
- Histologically confirmed metastatic adenocarcinoma of the breast (seeTNM staging Appendix I) that is ER and/or PR positive as determined in local laboratories at each investigator site (central verification of ER status will be performed after the patient starts treatment
- A tissue block from either the metastatic or primary tumor site is required.
- WHO performance status (PS) 0-2
- Patients must not be pregnant or breast-feeding. A negative pregnancy test is required within 7 days prior to randomization if pre- or peri-menopausal. Postmenopausal patients are defined as:
- natural menopause with last menses \> 1 year ago,
- radiation induced oophorectomy with last menses \> 1 year ago,
- chemotherapy induced menopause with 1 year interval since last menses, or
- serum FSH and LH and plasma estradiol levels in the postmenopausal range for the institution.
- bilateral oophorectomy
Exclusion
- Patients cannot be on hormone replacement therapy or received prior chemotherapy for metastatic disease.
- Patients previously treated with a Tyrosine Kinase inhibitor or have evidence of an active interstitial lung disease are not eligible.
- Treatment with LH-RH analog.
- Laboratory values as follow Bilirubin \>1.5 times upper limit of normal ULN, alanine amino transferase (ALT) or aspartate amino transferase (AST) \>2.5 times the ULN if no demonstrable liver metastases, or \>5 times the ULN in the presence of liver metastases
- Bone marrow function: WBC \<1500 mm3
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2015
Estimated Enrollment :
317 Patients enrolled
Trial Details
Trial ID
NCT00229697
Start Date
October 1 2003
End Date
June 1 2015
Last Update
October 5 2015
Active Locations (55)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Berkeley, California, United States
2
Research Site
Palm Springs, California, United States
3
Research Site
St Louis, Missouri, United States
4
Research Site
New York, New York, United States